Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 9012345...102030...Last »

New York sues OxyContin maker Purdue Pharma

New York state sued Purdue Pharma LP, accusing the OxyContin maker of widespread fraud and deception in the marketing of opioids, and contributing to a nationwide epidemic.

Read More »

Bayer teams up with Evotec, Haplogen

Collaboration partners Evotec AG and Haplogen GmbH announced that Haplogen will enter into a multi-year drug discovery and development deal with Bayer AG to focus on pulmonary diseases.

Read More »

Outcome Health Announces Partnership with American Liver Foundation to Promote Updated Screening Recommendations for Hepatitis C

Outcome Health announced a partnership with the American Liver Foundation to raise awareness of liver disease, specifically hepatitis C.

Read More »

Orchard raises $150 million to expand

Orchard Therapeutics raised a further $150 million to fund the biotech company’s work in gene therapy, building on earlier fundraisings worth more than $140 million.

Read More »

Japan’s Astellas Acquires U.K.-Based Quethera

Astellas Pharma Inc. plunked down nearly $109 million to snap up privately held Quethera Ltd. and the gene therapy company’s novel treatments for glaucoma and other ocular disorders.

Read More »

Artios Snags $84 Million to Advance DNA Damage Response Cancer Treatments

Artios Pharma received a financial boost from Pfizer, AbbVie and Novartis through an $84 million (£65 million) Series B funding.

Read More »

Gemphire Plunges After Investigational Drug Worsens Liver Fat Levels in Pediatric NAFLD Trial Patients

Shares of Gemphire Therapeutics crashed 73 percent in premarket trading after the company revealed its mid-stage non-alcoholic fatty liver disease treatment for pediatric patients actually worsened the disease in some patients.

Read More »

GW Pharmaceuticals Slaps Price Tag on Cannabis-Based Epilepsy Drug

GW Pharmaceuticals revealed a $32,500 price for the company’s cannabis-based epilepsy drug Epidiolex.

Read More »

Boston Scientific Continues M&A Spree

Boston Scientific Corp. forked over up to $160 million to acquire California stent maker Veniti Inc. The deal marks the third acquisition for Boston Scientific in two months.

Read More »

AstraZeneca settles Texas drug lawsuits

AstraZeneca agreed to settle two lawsuits brought by the state of Texas claiming that the drugmaker fraudulently marketed the antipsychotic drug Seroquel and Crestor for high cholesterol.

Read More »

Novo Nordisk Q2 2018 sales disappoint

Sales of some of Novo Nordisk’s key drugs in second-quarter 2018 fell short of expectations and the drugmaker said prices in the key U.S. market would be lower in 2019.

Read More »

From “Jeans to Genes”: Dyadic CEO Discusses How To Revolutionize Biopharma Manufacturing

Mark Emalfarb – founder, chairman and chief executive officer of Jupiter, Florida-based Dyadic International – believes he knows how to revolutionize biopharma manufacturing.

Read More »

Akouos Raises $50 Million Series A Financing and Expands Team to Advance Precision Genetic Therapies That Restore and Preserve Hearing

Akouos, a precision genetic medicine company developing gene therapies that restore and preserve hearing, today announced that the company raised $50 million in Series A financing.

Read More »

Scandal-hit Chinese vaccine maker Changsheng started falsifying records in 2014: Xinhua

Changsheng Bio-technology Co. Ltd. – a vaccine maker at the center of a safety scandal in China – began falsifying production records for its rabies vaccine in April 2014, state news agency Xinhua reported.

Read More »

Pharma and Biotech Companies Provide Top Salaries: Survey

The Business Journals compiled a list of the 25 companies across the United States with the highest median salary for employees, and more than half were in the pharma or biotech industries.

Read More »

Regeneron to invest $100 million in bluebird, jointly develop cancer therapies

Regeneron Pharmaceuticals Inc. will invest $100 million in cancer drug developer bluebird bio Inc., and the companies will jointly develop new cell therapies for cancer.

Read More »

VIVUS Appoints Kenneth Suh as President

  August 06, 2018 07:30 ET | Source: VIVUS, Inc.     CAMPBELL, Calif., Aug. 06, 2018 (GLOBE NEWSWIRE) — VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced the appointment of Ken Suh to the position of President.  Previously, Mr. Suh was President and CEO of Willow Biopharma Inc., a wholly-owned subsidiary of […]

Read More »

New Partnership Formed to Develop First-in-Class Gene Therapy for Cystic Fibrosis

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium – consisting of Imperial College London and the Universities of Oxford and Edinburgh – Imperial Innovations, and Oxford BioMedica announced a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis.

Read More »

Impact Therapeutics Raises $30 Million in Series C

Impact Therapeutics, headquartered in Nanjing, China, completed a Series C financing round worth $30 million. The round was led by Decheng Capital with participation from Lilly Asian Ventures.

Read More »

Almirall inks $650 million U.S. deal with Allergan

The Spanish pharmaceutical company Almirall agreed to buy five dermatology brands from U.S. company Allergan for up to $650 million in cash.

Read More »

Page 1 of 9012345...102030...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2018 Focus: Biotech, Payer Access, DTC and more!


Ad Right Bottom

Main Navigation